The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1b, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1b through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1b, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1b appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1b, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1b as a key enhancer of RET physiologic and pathologic activities.
Introduction
RET is a proto-oncogene encoding a receptor tyrosine kinase (RTK) that forms a transmembrane receptor complex with the glial cell line-derived neurotrophic factor (GDNF) coreceptors a (GFRa 1À4 ) for the GDNF ligands (Airaksinen and Saarma, 2002) . This transducing complex bridges two molecules of RET together and, by triggering their transphosphorylation at specific tyrosyl residues, recruits either adaptor or effector proteins (Ichihara et al., 2004; Arighi et al., 2005) and activates several downstream cascades. Ret signaling is critical to the neural crest and excretory system development (Arighi et al., 2005) . The two major alternatively spliced isoforms (RET-9 or short, 1072 aa; RET-51 or long, 1114 aa) differ at their cytoplasmic tail and, by recruiting a specific set of adaptors, exhibit a distinct role in mouse development (de Graaff et al., 2001) .
Specific RET mutations are implicated in several pathogenic disorders. Activating germline mutations at specific amino-acid residues are responsible for hereditary multiple endocrine neoplasia (MEN) syndromes (MEN2A, MEN2B and FMTC), while loss-of-function mutations confer predisposition to Hirschsprung's disease (HSCR) (Arighi et al., 2005) . Moreover, somatic chromosomal rearrangements at the RET locus, present in about one-third of papillary thyroid carcinomas (PTCs), lead to aberrant expression of chimeric proteins composed of RET cytoplasmic domain fused to the 5 0 -region of unrelated donor genes (Alberti et al., 2003) . These oncogenes, referred as RET/PTCs, are constitutively activated through ligand-independent dimerization and subsequent transphosphorylation, and lead to neoplastic transformation (Arighi et al., 2005) . They have been extensively studied to identify the cytoplasmic mediators recruited by RET-specific docking sites. Several interacting proteins, such as PLC-g, GRB2, GRB7, GRB10, SHC, Enigma, IRS1/2, FRS-2, SRC, SHANK3, DOKs, PDK1 and STATs (Takahashi, 2001; Arighi et al., 2005) have been so far identified, with certain adaptors exhibiting binding specificity for distinct RET isoforms. The recruitment of most transducers has been demonstrated to be crucial for activation of RET downstream pathways, including RAS/MAPK, p38a/JNK, PI3K/Akt and others typical of RTKs (Ichihara et al., 2004) , and cellular responses. However, the complexity of mechanisms regulating RET intracellular signaling appears to suggest new functional links between RET and its mediated pathways.
To study novel mediators of RET signaling, SH2B1b (formerly SH2-Bb) was identified as RET-binding protein through two-hybrid screening methodologies (Donatello et al., 2004; Zhang et al., 2006) . SH2B1b is a member of the structurally related SH2B family of adaptor proteins, characterized by a SRC homology 2 (SH2), a pleckstrin homology (PH) domain (Osborne et al., 1995; Riedel et al., 1997) , and a recently identified 'phenylalanine zipper' dimerization domain (DD) (DhePaganon et al., 2004) . Genetic disruption of the SH2B1 gene results in obesity, type-II diabetes and impaired fertility (Duan et al., 2004; Ren et al., 2005) . Four SH2B1 splice variants have been identified in mouse (a, b, g and d) , and three in humans (a, b and g) (Yousaf et al., 2001) , coding for polypeptides with distinct Cterminal sequences and specific biological properties. The b isoform has been reported as a binding partner for janus kinase (JAK), platelet-derived growth factor receptor (PDGFR), insulin-like growth factor 1 receptor (IGF1R), fibroblast growth factor receptor (FGFR), growth hormone receptor (GHR), insulin receptor (IR) and nerve growth factor receptor (NGFR) (Rui et al., 1997; Rui and Carter-Su, 1998; Wang and Riedel, 1998; Ahmed and Pillay, 2001; Qian and Ginty, 2001) , but is unable to associate with epidermal growth factor (EGFR) (Yousaf et al., 2001) . Its recruitment by the above tyrosine kinase (TKs) is mostly mediated by its SH2 domain. At variance with the majority of adaptor proteins acting downstream to RTKs, SH2B1b was shown to enhance autophosphorylation of IR, NGF receptors and cytokine receptor-associated JAK2 (Qian and Ginty, 2001; Ahmed and Pillay, 2003) , as well as to potentiate NGF-induced neuronal differentiation (Qian et al., 1998) . Consistently, leptin (through JAK2) and insulin sensitivity were found positively regulated by SH2B1 in mouse (Duan et al., 2004; Ren et al., 2005) .
In this study, we show that RET isoforms and their oncogenic derivatives associated to thyroid carcinomas, bind and phosphorylate SH2B1b. We provide evidence that coexpression of this adaptor increases RET autophosphorylation, kinase activity and downstream signaling, thus potentiating its differentiating and transforming ability, and give some insights into the mechanisms underlying these processes. Furthermore, we report that SH2B1b coexpression protect RET oncoproteins by specific RET inhibitors.
Results
RET oncoproteins bind and phosphorylate SH2B1b through a RTK-dependent mechanism RTKs' adaptors/effectors are known to interact with their intracellular domain. To identify new potential RET-binding proteins, we used the RET/PTC2-iso9 protein fused to the GAL4-DBD as bait, and screened a GAL4 activation domain-tagged human placenta cDNA library by yeast two-hybrid system. RET/PTC2 oncogene arises from somatic rearrangements between the RET intracellular portion and the 5 0 -end of PRKAR1A (encoding the R1a subunit of PKA) in PTC (Bongarzone et al., 1993) (Figure 1a) . The 21 clones identified as specifically interacting with RET/ PTC2 (and not with the unrelated GAL4-DBD-lamin) correspond to known RET cofactors, such as SHC, PLCg, GRB7, GRB10, Nck and p85a(PI3K), and to novel putative interacting proteins. Among them, two clones were a 639-and a 474-bp overlapping fragments, mapping at the 3 0 -end of SH2B1 cDNA. The isolated region includes the entire SH2 domain of SH2B1 and a small portion of flanking sequence (463-670 aa sequence), which allows identification of the isolated clones as coding for the SH2B1b isoform ( Figure 1a ) (Donatello et al., 2004) .
To rule out the contribution of the RIa portion in RET/ PTC2 interaction with SH2B1b, we tested the ability of the two SH2Bb1 clones to interact with the RET/ PTC2(236-595) construct ( Figure 1a ). This construct, which encompasses both the functional RET TK domain and the C-terminal tail (aa sequence 714-1071 of proto-RET), retained the ability to bind SH2B1b, thus indicating that RET intracellular region is directly involved in the interaction with the docking protein (data not shown).
To confirm the specificity of this interaction, we pulled-down lysates of RET/PTC2-transfected cells with GST-fused SH2B1b proteins (Figure 1b) , and evaluated the extent of binding. RET/PTC2 directly binds the wild-type adaptor, while its SH2Bb1 R555E counterpart, mutated at the FLVR motif of the SH2 domain and unable to bind active RTKs (Rui and Carter-Su, 1999) , showed no interaction. Furthermore, the inability of RET/PTC2 to be retained by the resin-bound SH2B1b upon cell lysate treatment with phosphatase, strongly indicates that RET phosphorylation is required for this interaction.
As proto-RET and its oncogenic derivatives recruit several adaptors/effectors, and SH2B1b has been described as an adaptor of several TKs, we sought to demonstrate whether (i) SH2B1b interaction with RET is associated to specific RET isoforms; (ii) it is kinaseactivity-dependent; and (iii) RET/PTC2 directly phosphorylates SH2B1b. We therefore cotransfected 293T cells with either the short (À9) or the long (À51) RET/ PTC2 isoform and the GFP-tagged SH2B1b (or empty vector). Both RET/PTC2 isoforms, but not RET/ PTC2 K282R kinase-dead, coprecipitated with SH2B1b and not with its SH2-inactive mutant (Figure 1c ). Transmembrane forms of RET, including proto-RET (not shown), and MEN2A-and MEN2B-associated constitutive active mutants (Figure 1d ), were all able to interact with the Myc-tagged SH2B1b, which indeed excluded undesired tag-specific effects. A significant level of phosphorylated adaptor was detected in RET/ SH2B1b-wt coprecipitates.
A further demonstration of SH2B1b phosphorylation by RET was provided by immunoprecipitating lysates from RET/PTC2-and mock-transfected cells with antiserum to RET and assaying the kinase activity on purified GST-SH2B1b as substrate (Figure 1e ). After blotting, we observed that the wild-type adaptor protein yielded a distinct [ 32 P]-labeled band, while no phosphorylation was detected with the SH2B1b R555E mutant. Together, the data obtained in vitro and in intact cells demonstrated that both kinase activity and a functional SH2 domain are indispensable for SH2B1b recruitment to RET, which in turn phosphorylates the adaptor.
Y905 and Y981 on RET are major determinants of its interaction with SH2B1b
The complex pattern of RET autophosphorylation has been already revealed. To map on RET the tyrosines putatively binding SH2B1b, affinity-bound GSTSH2B1b resin was used to pull-down RET/PTC2 constructs devoid of distinct autophosphorylation sites (shown in Figure 2a ). Kinase-dead K282R and truncated N538 mutants, Y424F/Y429F, Y505F/539F and Y424D/Y429E (DE) double mutants were also included in the assay. RET/PTC2 DE , which mimics constitutive autophosphorylation in the activation loop (Gryz and Meakin, 2000) , maintains comparable kinase activity with the RET/PTC2 (not shown), but deprives the corresponding residues of potential docking activity. RET/PTC2 N538 , lacking the C terminus corresponding to residues 1015-1071 on RET, is devoid of the 1015 and 1062 docking sites, but still able to undergo autophosphorylation. As shown in Figure 2b , mutation at Y276 
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RET/PTC2 iso9 aa463-aa670 (MEN2B-associated) (d) cotransfected with SH2B1b constructs in 293T cells, were immunoprecipitated with aRET or aMYC, followed by immunoblotting with aRET, aGFP, aMYC and aphosphotyrosine (apTyr) antibodies. KR, K282R mutant. WCL, whole-cell lysate. Iso9 and Iso51, short and long RET isoforms. (e) SH2B1b is directly phosphorylated by RET in vitro. RET/PTC2 transiently transfected in 293T cells was immunoprecipitated with aRET and subjected to kinase assay on GST, GST-SH2B1b and GST-SH2Bb RE proteins. Figure 2c , the adaptor protein was present and phosphorylated in immunoprecipitates from RET/PTC2-Y505F and, at lesser extent, from Y429F-transfected cells. In contrast, no SH2B1b was detected in RET precipitate from FF mutant. Therefore, these results support a RET/SH2B1b interaction mediated by both Y905 and Y981 of RET kinase domain.
SH2B1b enhances RET phosphorylation and kinase activity
We have observed that cotransfection of RET/PTC2 with SH2B1b increases RET protein level and enhances its autophosphorylation. To study this effect better, we cotransfected RET/PTC2-iso51 with either SH2B1b or GRB2, as a control. As shown in Figure 3a , coexpression of GRB2, an adaptor known to bind RET-iso51 (Alberti et al., 2003) , had no effect on RET autophosphorylation. In contrast, SH2B1b, but not its R555E inactive mutant, RET/PTC2 was co-transfected with wild-type SHP-1 or its inactive C455S mutant, together with increasing amounts of the adaptor vector (0-1.5 ratio over RET cDNA). RET phosphorylation was detected on WCLs with apTyr.
GFP-SH2B1β
SH2B1b enhances RET signaling S Donatello et al dramatically increased tyrosine phosphorylation and raised protein levels. To investigate whether SH2B1b directly affects RET kinase activity, an in vitro kinase immunocomplex assay was performed by preincubating RET/PTC2 and GSTSH2B1b with or without cold adenosine triphosphate (ATP), and by adding the myelin basic protein (MBP) substrate and [g 32 -P]ATP. Assembling of RET/SH2B1b-wt complex in presence of ATP, which allows phosphorylation of the adaptor (see Figure 1e) , resulted in improved incorporation of [ 32 P] by both RET/PTC2 and MBP (Figure 3b, right panel) . At variance, similar levels of labeled MBP were observed when ATP was added together with the substrate (100-fold molar excess over the recombinant SH2B1b), indicating that efficient phosphorylation of the adaptor is required to enhance RET activity. To evaluate the contribution of SH2B1b to RET activity in intact cells, we determined the effect of the TK inhibitor PP1 (Carlomagno et al., 2002) on RET/ PTC2 coexpressed or not with the adaptor. As expected, SH2B1b-wt improved its kinase activity (up to 2.5-fold), even in the presence of PP1, which induces a dosedependent inhibition of RET (Figure 3c ). These data, while suggesting that SH2B1b incorporates in a fully active complex with RET, demonstrate that the adaptor markedly protected the kinase from the inhibitory effect of PP1 compound at relative low inhibitor dose (0.5 mM). Comparable results were obtained by using the RPI-1 (Cuccuru et al., 2004 ) specific RET blocker (not shown), and by assessing RET-driven transcriptional activity in presence of TK inhibitors (Supplementary Figure 1S) .
Further, as SHP-1 protein tyrosine phosphatase modulates the activity of RET-derived oncogenes by reducing their phosphorylation (Hennige et al., 2001) , we asked whether SH2B1b interaction with RET may modulate SHP-1-mediated dephosphorylation in intact cells. We coexpressed RET/PTC2 and SHP-1 (or its inactive C455S mutant (Roccato et al., 2005) together with increasing amounts of SH2B1b, and examined the steady-state phosphorylation of RET. As shown in Figure 3d , in absence of SH2B1b, RET/PTC2 phosphorylation was greatly reduced in cells transfected with SHP-1-wt. In presence of the adaptor protein, the SHP-1-expressing cells exhibited a SH2B1b concentrationdependent RET phosphorylation. Consistently, no significant dephosphorylation was detected in cells transfected with the C455S mutant. This finding suggests that the complex formed by the interaction of RET with the adaptor protein might increase its autophosphorylation by protecting it from the action of phosphatases.
We also evaluated whether the elevated levels of RET observed in presence of SH2B1b were due to a stabilizing effect of the binding complex. The steadystate RET/PTC2 levels were increased by cotransfection with SH2B1b-wt, but no significant augmentation of its half-life was observed in protein turnover studies with cycloheximide protein translation blocker (Supplementary Figure 2S ). Nevertheless, the wild-type adaptor had a positive effect on the oncoprotein level, as the increase in RET expression by SH2B1b was maintained during the cycloheximide treatment.
RET activation of downstream effectors is enhanced by SH2B1b
The observed effects of SH2B1b on RET autophosphorylation and kinase activity suggest an upregulation of RET downstream signaling through enhancement of both the recruitment of docking proteins and the activation of its direct substrates. Therefore, we first studied the effect of RET/SH2B1b complex on STAT3 activation, a direct substrate of several TKs, which mediates oncogenesis through phosphorylation of its Y705 residue (Bromberg et al., 1998) . We assayed the extent of STAT3 activation by immunoblotting, and studied transactivation of the responsive pm67
4 -and pCD1-luciferase reporter constructs, including respectively a high-affinity binding site for activated STAT3 (Besser et al., 1999) and the 1700-bp cyclin D1 promoter (Lee et al., 1999) , which requires STAT3 and other factors for full activation. As shown in Figure 4a , at low RET/PTC2 expression levels in HeLa cells we could barely detect activation of endogenous STAT3, and measured a negligible effect on m67-and CD1-driven activity (Figure 4b ). Coexpression of SH2B1b resulted in a marked phosphorylation of endogenous STAT3, more elevated RET levels, and a significant increase in pm67 4 luc and pCD1luc transactivation (respectively by five-and threefold) over its R555E mutant. This trend was confirmed by exogenous STAT3 expression.
Further, to assess whether increased RET phosphorylation by SH2B1b may positively modulate recruitment of effectors, we assayed the phosphorylation of Shc, a key transducer of RTKs, that associates to RET through the Y1062 docking site (Arighi et al., 1997) . Shc was immunoprecipitated from cells transfected with either RET/PTC2 or RET/PTC2 Y586F , in combination with SH2B1b, and the Tyr-phosphorylation of the immunocomplexes was evaluated. The SH2B1b-Y439F/Y494F (FF) double mutant was included to test whether these tyrosines, required for the biological activity of JAK/and PDGFR/SH2B1b complexes (O'Brien et al., 2003) , and putative binding sites for the SHC SH2 domain (YXXL/I motif) (Ravichandran, 2001) , may influence the binding of RET/SH2B1b to Shc. As expected, RET/PTC2, but not its Y586F mutant (devoid of Shc docking site, Y1062 on RET), binds to and phosphorylates Shc isoforms (Figure 4c ). Consistent with its positive effect on RET, Shc phosphorylation was significantly enhanced by SH2B1b-wt coexpression, an effect also observed with the FF mutant. This result thus excludes the requirement of these residues for the SH2B1b effect on Shc recruitment. Intriguingly, the inability of Y586F mutant to recruit Shc was partly reversed by SH2B1b, thus suggesting that RET/SH2B1b interaction may unveil additional docking sites yet to be explored.
A further evidence of positive effect of SH2B1b on RET-induced signaling comes from comparative proteomic studies performed on lysates of RET/PTC2-and PTC2/SH2B1b-transfected cells. Proteins immunopurified with immobilized anti-pTyr antibody were analysed by peptide mass fingerprinting (Gorla et al., 2006) , and 29 phosphorylated proteins, including transducers, transcription factors, proteins involved in cytoskeleton organization and in RNA metabolism, were identified as specifically phosphorylated by RET/PTC2, mostly representing novel substrates and known transducers phosphorylated by RET. The same phosphoproteins showed a significantly increased staining intensity in cells coexpressing RET/PTC2 and SH2B1b (Supplementary Figure 3S ). These results suggest a quantitative effect of SH2B1b on RET-induced phosphoproteome, without altering its specificity.
SH2B1b enhances RET-mediated biological activity RET/PTC oncogenes, isolated as transforming genes from thyroid cancers (Alberti et al., 2003) , are exclusive to PTC. By evaluating SH2B1b expression in a thyroid environment, we found that equivalent levels of SH2B1 mRNA are expressed in RET/PTC1-infected human thyrocytes and in their parental cells (microarray data deposited in the ArrayExpress database, E-MEXP-429). In addition, the specific expression of the b-isoform was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) in thyroid tumorigenic and matched normal tissues (not shown). To determine whether SH2B1b impacts on RET-induced transformation, we stably cotransfected NIH3T3 cells with RET/PTC2 and SH2B1b, and isolated colonies expressing distinct combinations of RET and the adaptor. Among them, we chose one SH2B1b-positive clone (S1); one clone expressing high RET/PTC2 level (R1); and three clones expressing low RET/PTC2 amounts, but distinct level of the adaptor: R2, with no SH2B1b; RS1, showing intermediate SH2B1b level; RS2, with the most adaptor protein (Figure 5a ). The corresponding cells were plated for growth in soft agar, and transformants were thus detected (Figure 5b ). S1 was unable to form colonies of more than 8-16 cells, as parental NIH3T3, whereas RET/PTC2 and RET/SH2B1b coexpressing cells formed colonies of more than 50 cells. As expected, the colony size in R clones was related to the oncogene levels. Interestingly, RS1 showing equivalent oncogene expression with the R2 clone and intermediate SH2B1b, clone showing higher SH2B1b expression than RS1, resulted in considerable large colonies spreading through the matrix. Overall, the size of transformed colonies on soft-agar parallels the extent of oncogene phosphorylation, which is augmented by SH2B1b in the RS clones. Thus, coexpression of the adaptor protein potentiates RET/PTC2 transforming ability by enhancing its autophosphorylation. SH2B1b has been reported to enhance the neuronal differentiation of rat PC12 pheochromocytoma induced by the activated NGF receptor TrkA (Rui and CarterSu, 1999) . Since activated RET kinases also cause differentiation of PC12 cells (Borrello et al., 1995) , we assessed the effect of SH2B1b on RET-induced neurite elongation. PC12 cells, expressing endogenous proto-RET and transfected with its GFR1a coreceptor exhibited a discrete neuronal differentiation by GDNF, as assessed by both neurite outgrowth and activation of the pvgf8luc reporter (a marker of neuronal differentiation upstream of the luciferase gene) (Canu et al., 1997) , and a significant enhancement of the number of differentiated cells and neuritis lengths by SH2B1b (Supplementary Figure 4S) . This effect, which is in accordance with what previously reported (Zhang et al., 2006) , was best evaluated by the higher vgf8 response. Moreover, as GDNF can signal independently of RET through GFRa, we tested the effect of constitutively active RET C634R (associated to MEN2A) and RET/ PTC2 on GDNF-independent differentiation. The enhancing effect of SH2B1b was confirmed, as assessed by luciferase activity (Figure 6a ), and activation of RET downstream effectors was also augmented by the adaptor. In fact, pSTAT3 and pSTAT1 levels are markedly enhanced in cells coexpressing RET/PTC2 and SH2B1b-wt, as well as pERK1/2 downstream to Ras/MAPK pathway (Figure 6b ). Consistent with previous experiments, RET expression was found to be upregulated in PC12 cells cotransfected with the adaptor, which might contribute to the overall differentiation enhanced by the RET/adaptor complex.
As SH2B1b in vitro binding to RET is affected by specific Y to F mutations (see Figure 2) , we investigated whether mutations at RET docking sites may downregulate the effect of SH2B1b on PC12. RET/PTC2 short and long isoforms stimulated comparable differentiation, as measured by luciferase, and SH2B1b coexpression increased this activity by approximately fourfold (Figure 7a ). While RET/PTC2 mutants RET/ PTC2-Y505F, -Y539F and -Y505F/Y539F induced differentiating effect comparable with the wildtype kinase, others, as RET/PTC2-Y276F, -Y586F, -Y424F, -Y429F, -Y424F/Y429F and -Y429F/Y505F, as well as the negative control mutant -K282R, displayed lower or no differentiating activity on PC12. Coexpression of SH2B1b stimulated significantly (from four-to sixfold) the pvgf8luc response associated to the single mutants, and to RET/PTC2 Y424F/Y429F and RET/PTC2 Y505F/Y539F double mutants, while the RET/ PTC2 Y429F/Y505F -driven differentiation was negligibly affected. As expected, the activity of kinase-dead K282R control was unaffected by the adaptor. These data reveal that either Y429 or Y505 residues (Y905 and Y981 in proto-RET) are required for functional SH2B1b recruitment, and appear to mediate its effect on RET-induced biological activity. Accordingly, as shown in Figure 7c , ERK1/2 phosphorylation elicited by RET/PTC2 is enhanced by SH2B1b in RET/PTC2 Y505F and, at lesser extent, in RET/PTC2 Y429F single mutants cotrasfection experiments, as in -wt and -Y586F controls. The enhancing effect on ERKs is instead impaired by mutations at both Y429 and Y505 residues of the oncogene. Figure 5S) . These mutants display an enhancing activity on RET/PTC2-driven differentiation comparable with the wild-type protein (Figure 7b ), suggesting that both the above tyrosines and dimerization of the adaptor 
Discussion
SH2B1b, a splicing product of SH2B1 gene primarily identified as substrate of the TK JAK2 (Rui et al., 1997) , has been recognized as an adaptor for several RTKs (Rui et al., 1997; Rui and Carter-Su, 1998; Wang and Riedel, 1998; Ahmed and Pillay, 2001; Qian and Ginty, 2001; Yousaf et al., 2001) . We previously reported its identification, via yeast two-hybrid system, as a putative adaptor for both proto-RET and RET/PTC2 oncogene (Donatello et al., 2004) . A clear demonstration that interaction of SH2B1b with proto-RET is involved in signaling of GDNF-induced neuronal differentiation has been recently provided by He and co-workers (Zhang et al., 2006) . The results reported in this paper, while supporting their findings, add novel information that highlights the importance of SH2B1b in mediating RET-induced differentiation and neoplastic transformation, and gives some insights into the mechanisms underlying their interaction. RET short and long isoforms, exhibiting distinct physiological role and common and isoform-specific transducers (de Graaff et al., 2001) , as well as their thyroid carcinoma-associated oncogenic forms, incorporate in a fully active complex with SH21Bb through the adaptor's SH2 domain. The active autophosphorylated RET is required for this interaction to occur. As a consequence, SH2B1b undergoes phosphorylation and RET displays increased phosphorylation and downstream signaling activation. Therefore, RET functions, including neuronal differentiation and cellular transformation, are positively modulated by SH2B1b. These findings may contribute to our understanding of RET signaling in development and carcinogenesis. RET mediates, in fact, several biological processes, including the development of the enteric nervous system, kidney organogenesis and spermatogenesis (Arighi et al., 2005) . Moreover, RET oncogenic activation is a crucial initiating event in thyroid cancers. Thus, the demonstration that SH2B1b is a binding partner for proto-RET, RET/PTC, and MEN2A-and MEN2B-associated oncoproteins, reveals this adaptor as a critical player of RET-driven signaling. Furthermore, similar to the SH2B1b's potentiation of specific pathways activated by NGF or insulin (Qian and Ginty, 2001; Ahmed and Pillay, 2003) , the upregulation by SH2B1b of RETactivated downstream pathways strongly supports the idea of a positive regulatory mechanism for this adaptor on RET activity. We have extended this concept by demonstrating that the RET/PTC-associated phosphoproteome is quantitatively enhanced by SH2B1b coexpression, in agreement with the increased TK activity of the adaptor/RET complex. Accordingly, the finding that the GDNF-dependent and -independent RET-induced neuronal differentiation is markedly enhanced by SH2B1b coexpression in PC12 cells (Zhang et al., 2006) and our results), appears a consequence of the general SH2B1b-mediated upregulation of RET signaling. This is consistent with the previously demonstrated effect on NGF-induced TRK phosphorylation and neurite outgrowth (Rui and Carter-Su, 1999; Qian and Ginty, 2001 ). Interestingly, transgenic mice expressing DN-RET display defective early spermatogenesis (Arighi et al., 2005) , a phenotype partly overlapping the impaired fertility of SH2B1-null mice (Ohtsuka et al, 2002; Duan et al., 2004) . Whether RET/SH2B1b complex is involved in spermatogenesis is an interesting point to be addressed.
The binding requirements for SH2B1b are yet to be fully elucidated. It has been reported that tyrosines within pYXXL/M motif of TK domains are putative binding sites for SH2B1b (Kong et al., 2002; Kurzer et al., 2004) . By addressing Y to F mutations in RET cytoplasmic region (see Figure 2a for comparison of tyrosine residues between proto-RET and RET/PTC2), we identified Y905 (within YVKR motif) and Y981 (YRLM motif) as crucial sites for SH21Bb binding. Mutations at either Y905 or Y981 significantly reduce RET binding to the adaptor in pull-down experiments. However, they appear to complement in intact cells, and the interaction is prevented only when both residues are mutated. Consistently, SH2B1b shows negligible effect on the poor neuronal differentiation induced by the RET Y905F/Y981F double mutant, while significantly enhancing the differentiating activity associated to single mutants. Our finding of Y905 and Y981 as a binding sites for the adaptor is partly in contrast with the previous observation that led to propose RET-Y981 as unique SH2B1b-docking site (Zhang et al., 2006) . Thus, our results are consistent with previous finding showing SH2B1b binding to pYXXL/M motif, and support the view that conserved tyrosines in the autocatalytic loop may be also required in order for RTKs to recruit members of SH2B family. In fact, SH2B1a and -g, and SH2B2 adaptors have been demonstrated to bind to phosphotyrosines within the YETD and YYRK motifs of the IR's activation loop (Kotani et al., 1998; Nelms et al., 1999; Hu et al., 2003) , and evolutionarily conserved in TrkA and IGF1R. RET-Y905 lies into YVKR sequence exhibiting elevate homology with an IR's motif. Although the poor binding of SH2B1b to RET-Y905F in vitro might also reflect its low tyrosine phosphorylation, a role as docking site for the activation-loop's tyrosine residues is demonstrated. Therefore, Y905 autocatalytic tyrosine may contribute both directly and indirectly to this binding.
Finally, the neuronal differentiation observed following SH2B1b coexpression, over the one associated to RET devoid of Y1062 multidocking site, is consistent with the binding of the adaptor to this mutant, and with the recruitment of SHC adaptor (required for RTKinduced differentiation) to this complex. Whether SH2B1b's phosphorylatable tyrosine residues are directly involved in the recruitment of SHC to its complex with RET 1062F is an interesting aspect to be investigated. Moreover, as RET loss-of-function alterations associated with HSCR disrupt the binding of transducer to SH2B1b enhances RET signaling S Donatello et al the multidocking site (Arighi et al., 2005) , it would be interesting to test whether SH2B1b could restore these partially impaired signals.
Clustering of SH2B proteins to RTKs increases their transphosphorylation and activity (Qian and Ginty, 2001) . Mutants deleted of the phenylalanine-zipper DD in the SH2B N-terminus (Dhe-Paganon et al., 2004) are unable to enhance NGF-mediated PC12 differentiation (Qian and Ginty, 2001) . We show that SH2B1b devoid of this domain, SH2B1b
D24À88
, exhibits reduced phosphorylation by RET/PTC2 and coprecipitation, but still enhances oncogene autophosphorylation and biological activity. This appears in agreement with previous results showing that the adaptor's SH2 domain binds to active phosphorylated TKs and enhances their autophosphorylation (Rui et al., 2000; Kurzer et al., 2004) , which might suggest a regulatory mechanism for the Nterminal portion of SH2B1b. Further investigations would help to elucidate the contribution of this domain to RET signaling.
A final important question is the impact of RET/ SH2B1b functional interaction in neoplastic processes of PTC-associated RET oncogenes. By testing the transforming ability of NIH3T3 cells cotransfected with RET/PTC2 and SH2B1b, we could demonstrate that growth of RET/PTC2-expressing clones on soft agar is enhanced by SH2B1b. In fact, cells expressing equivalent RET/PTC2 amounts show a direct relationship between RET autophosphorylation, the colony size and the level of the adaptor protein, thus suggesting a role for the adaptor in RET/PTC-driven transformation. This is further supported by the observed expression of SH2B1b in primary thyrocytes, the human cell type from which PTC arises through RET/PTC oncogenes (data not shown).
Taken together, by demonstrating that SH2B1b enhances RET-induced signaling and biological activities, we provide evidence and extend the concept that this adaptor is a key regulator exerting its action primarily on RTKs. Our studies give some insights into the understanding of the mechanisms by which SH21Bb upregulates RET activity: (i) by binding to and (ii) by preventing RET dephosphorylation by SHP-1 tyrosine phosphatase. We may hypothesize that SH2B1b, by protecting autocatalytic tyrosines from protein tyrosine phosphatases, enhances the steady-state autophosphorylation of RET and potentiates its catalytic activity. SHP-1, expressed in thyroid tissues, has been in fact shown to dephosphorylate RET, with consequent reduction of the transforming potential associated with RET MEN2A oncogene (Hennige et al., 2001) . Moreover, we have shown that SH2B1b binding to RET even hampers the action of TK inhibitors.
In conclusion, our investigation supports a role for SH2B1b as a key enhancer of RET activity. Since both loss-and gain-of-function pathogenic RET mutations are involved in human diseases, the possibility to enhance RET residual signals or to attenuate RETmediated oncogenic processes through SH2B1b adaptor may represent an intriguing possibility to address novel therapeutic strategies.
Materials and methods

Plasmid construction
The MYC-tagged full-length SH2B1b cDNA cloned in pRK5-vector was kindly provided by C Carter-Su (University of Michigan, Ann Arbor, MI, USA) (Rui and Carter-Su, 1999) . The GFP-tagged cDNA was derived by EcoRI-XhoI digestion and subcloning into pEGFPC3 vector (Clontech, Mountain View, CA, USA). The corresponding R555E, Y439F, Y494F, Y439F/Y494F (SH2B1b FF ) and D24-88 mutants were obtained by site-directed mutagenesis using the Quick Change sitedirected mutagenesis XL kit (Stratagene, La Jolla, CA, USA). The GST-SH2B1b and -SH2B1b R555E expression vectors were obtained by BamHI/EcoRI excision of the pRK5-SH2B1b plasmids and subcloning into pGEX4T2. Cloning of proto-RET-9, proto-RET-51, RET/PTC2-9, RET/PTC2-51 and RET C634R cDNAs into pRC/CMV mammalian expression vector was previously reported (Borrello et al., 1995; Arighi et al., 1997; Lorenzo et al., 1997) . RET/PTC2 Y586F , Y505F, Y539F, Y505F/Y539F and K282R mutants were described earlier (Borrello et al., 1996; Arighi et al., 1997 construct was obtained by PCR amplification of the 1-538 coding region and subcloned via HindIII/XbaI into pRC/ CMV. The pcDNA3hygro-RET/PTC2-9 construct was generated by XbaI excision from its pRC/CMV homolog and subcloning into the recipient plasmid. All mutant constructs were confirmed by sequencing. The pRK5RS-SHP-1 expression vector was provided by A Ullrich (Max-Planck-Institut, Martinsried, Germany), and its SHP-1 C455S derivative previously reported (Roccato et al., 2005) . The pcDNA3-GFRa1 plasmid was from DP Smith (University of Cambridge, Cambridge, UK). The FLAG-tagged STAT3 constructs in pRc/CMV (Bromberg et al., 1998) were a gift of J Darnell (The Rockfeller University, New York, NY, USA).
Antibodies and other reagents Antisera to RET (common I and II), raised against C-terminal epitopes were reported (Borrello et al., 1996) . Antibodies specific to and to isoform, to proto-RET (H-300), and to GFP (B-8) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-pTyr 4G10 mouse monoclonal antibody and anti-SHC were from Upstate Biotechnology (Charlottesville, VA, USA). Antibodies to phospho-ERK1/2 and total ERK1/2, to pSTAT3 and STAT3, to pSTAT1 and STAT1 were from Cell Signaling (Danvers, MA, USA). Anti-MYC (9E10) and anti-FLAG monoclonal antibodies were respectively from Calbiochem (San Diego, CA, USA) and from Sigma (St Louis, MO, USA). Goat anti-GFP antibody was from Rockland (Gilbertsville, PA, USA). GDNF was from Alomone Labs (Jerusalem, Israel). Sepharoseprotein A, Sepharose-protein A/G and Sepharose-glutathione beads, HRP-linked anti-IgG secondary antibodies, ECL reagents, and [g 32 -P]ATP (10 mCi/ml) were from Amersham Bioscience (Piscataway, NJ, USA).
Yeast two-hybrid screening
The full-length RET/PTC2 and RET(712-1071) were subcloned into the NdeI/SalI sites of pAS2-1 vector, downstream to the GAL4-DBD (Clontech). Human Placenta Matchmaker cDNA library, cloned into the EcoRI/XhoI sites of pACT2 yeast expression vector, was screened with the RET/PTC2 construct as a bait, according to the Matchmaker GAL4 TwoHybrid System protocol (Clontech). Positive colonies were SH2B1b enhances RET signaling S Donatello et al rescreened with the pAS2-1-RET(712-1071) construct, and prey fragments of positive clones were sequenced at both 5 0 -and 3 0 -end for identification.
Cell culture 293T embryo kidney and HeLa cervical carcinoma cells were grown on Dulbecco's modified Eagle's medium-based media plus 10% fetal bovine serum. PC12 rat pheochromocytoma cells were cultured in RPMI medium supplemented with 10% horse serum and 5% FBS. PC12 and 293T were maintained at 371C in 5% humidified CO 2 atmosphere, HeLa and NIH3T3 in 10% CO 2. Before experiments, PC12 cells were seeded at 50 000 cells/ cm 2 density on multi-well plates previously coated with Collagen type-IV (BD Bioscience, Franklin Lakes, NJ, USA).
Transient and stable transfections and soft-agar assay 293T cells seeded into 10-cm plates were cotransfected by the CaPO 4 precipitation method. Multi-well plates were transfected by Fugene6 lipid transfectant (Roche, Basel, Switzerland). Proteins were extracted 36-48 h post-transfection. Stable NIH3T3 cotransfectants expressing RET/PTC2 and GFP-SH2B1b gene, or combinations with their empty vectors, were obtained via Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) transfection of subconfluent cells with 2 mg each of plasmids carrying neomycin (pEGFPC3-SH2B1b) and hygromycin (pcDNA3hy-gro-RET/PTC2-9) resistance genes. Clones were isolated by G418 (0.5 mg/ml) and hygromicin (50 mg/ml) selection, and tested for their ability to growth in soft agar. Briefly, cells were suspended in complete selective medium containing 0.33% (w/v) Type-VII agarose (Sigma) and overlaid onto previously solidified 0.5% agarose in complete medium. Following two weeks culture, colonies were stained with 1 mg/ml p-iodonitotetrazolium-violet (Sigma), counted and photographed.
Immunoprecipitation, immunokinase and pull-down assays Cultured cells were lysed in ice-cold PLCLB buffer (50 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM ethylene glycolbis(b-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid, 10 mM Na 4 P 2 O 7 , 50mM NaF, 10% glycerol, 1% Triton X-100) supplemented with protease/phosphatase inhibitors. Cleared cell lysates (E1 mg protein) were incubated with the indicated antibodies and Sepharose-protein A/G beads, rotated for 3-4 h at 41C, washed three times with HNTG buffer (20 mM HEPES, pH 7.5, 140 mM NaCl, 10% glycerol, 0.2% Triton X-100) plus protease/phosphatase inhibitors and boiled 5 min in sodium dodecyl sulfate (SDS) sample buffer. The solubilized proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) on polyacrylamide gels, western blotted with selected antibodies and detected by ECL. Lysate aliquots (40 mg) were also immunoblotted to evaluate the level of specific protein expression. Immunokinase assays were performed on cell lysates incubated with antibody to RET-9 (C-19) and collected on Sepharose-protein A beads after rotation (3 h, 41C), two washes with HNTG buffer, and two with kinase buffer (50 mM HEPES pH 7.2, 1 mM MgCl 2 , 5 mM MnCl 2 , 1 mM dithiothreitol, 0.2 mM phenylmethanesulfonylfluoride, 0.2 mM Na 2 VO 7 ). The reaction was carried out in 30 ml of kinase assay buffer containing 2 mM ATP, 50 mM MBP and 2.5 mCi of [g
32
-P]ATP, and proceeded for 20 min at 41C before stopping with 10 ml of 4 Â SDS sample buffer and boiling. Samples were separated on 12% polyacrylamide gel, transferred onto nitrocellulose membrane, and radioactive blots exposed to phosphorscreen ( 32 P-labelled bands were quantified by densitometric scanning on Thyphoon 8600 (Amersham) and normalized to the corresponding RET protein). To evaluate the in vitro phosphorylation of SH2B1b protein by RET/PTC2, the kinase reactions were carried out in the kinase assay buffer added with 2 mM ATP, 5 mM reduced glutathione, 2 mg of resin-bound GST-SH2B1b and 2.5 mCi of [g
-P]ATP. Following separation on 7.5% gel and blotting onto membranes, the radioactive blots exposed to phosphorscreen. Pull-down experiments were performed by using GST-SH2B1b protein and its R555E mutant counterpart. Briefly, RET-transfected 293T cells were lysed in TNE-T 1% lysis buffer (50 mM Tris, pH 7.4, 140 mM NaCl, 2 mM ethylenediaminetetraacetic acid, 40 mM NaF, 1% Triton X-100 plus protease/phosphatase inhibitors), rotated 4 h on immobilized GST-SH2B1b beads, washed twice with TNE-T 0.5%, and immunoblotted for detection of bound RET proteins, in parallel with the respective inputs.
Proteomic analysis
Lysates from transfected 293T cells were pooled (B10 mg of protein) and precleared with Sepharose-protein A. Phosphorylated proteins were affinity-purified with agarose-coniugated antibody to pTyr (Sigma). Following 3 h incubation, the beads were washed trice with HNTG buffer, boiled in SDS sample buffer, and the eluted phosphoproteins resolved by SDS-PAGE (4-12% precast NuPAGE gel, Invitrogen) before standard silver staining.
Protein bands were picked and treated overnight with sequencing-grade modified trypsin (Promega, Madison, WI, USA) and identified by peptide mass fingerprint method. MALDI-TOF mass spectrometry analysis was performed on a Voyager-DE STR (Applied Biosystems), and spectra analysed with ProFound software (http://www.expasy.org/tools/ProFound) searching in nonredundant protein database (NCBI). Peptide mass tolerance was 720 p.p.m.
Reporter assay PC12 and HeLa cells, seeded on 12-wells plates in complete medium with no antibiotics, were transfected respectively via Cellfectin (Invitrogen) and Fugene6, with combination of reporter vectors, pRL-TK co-reporter, RET and SH2B1b constructs. pvgf8luc (Canu et al., 1997) , pCD1luc (Lee et al., 1999) and pm67 4 TATAluc (Besser et al., 1999) reporters were respectively provided by R Possenti (Tor Vergata University, Rome, Italy), R Pestell (Georgetown University, Washington, DC, USA) and J Darnell. At 12-16 h post-transfection, PC12 cells were treated with GDNF and left 48 h before neurite outgrowth and reporter activity were evaluated. Luciferase activity was measured with the dual-luciferase assay kit (Promega). The activity associated to the reporter plasmids was normalized to the activity of the Renilla luciferase.
